A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant

Vincenzo De Falco,Maria Iole Natalicchio,Stefania Napolitano,Nicola Coppola,Giovanni Conzo,Erika Martinelli,N. Zanaletti,P. Vitale,E F Giunta,Maria Teresa Vietri,P.P. Vitiello,D. Ciardiello,Anna Marinaccio,Ferdinando De Vita,Fortunato Ciardiello,Teresa Troiani

A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant

2019

Vincenzo De Falco
Maria Iole Natalicchio
Stefania Napolitano
Nicola Coppola
Giovanni Conzo
Erika Martinelli
N. Zanaletti
P. Vitale
E F Giunta
Maria Teresa Vietri
P.P. Vitiello
D. Ciardiello
Anna Marinaccio
Ferdinando De Vita
Fortunato Ciardiello
Teresa Troiani

AbstractIntroduction:Fluoropyrimidines such as 5-fluorouracil (5-FU) and its orally active prodrug, capecitabine, are widely used in the treatment of gastrointestinal cancer, including colorectal cancer. Dihydropyrimidine dehydrogenase (DPD) plays an important role in the 5-FU metabolism. Dihydropyr

Keywords:

Medicine
Physical therapy
Diabetes mellitus
DPYD
Oncology
Toxicity
Internal medicine
Capecitabine
Prodrug
Dihydropyrimidine dehydrogenase
Colorectal cancer
Gastrointestinal cancer

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations